A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone

Pierre Alberto, Bernadette Mermillod, Eli Kaplan, Aron Goldhirsch, Jean Pierre Obrecht, Felix Jungi, Georg Martz, Laurent Barrelet, Franco Cavalli

Research output: Contribution to journalArticle

Abstract

In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.

Original languageEnglish
Pages (from-to)423-428
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number4
DOIs
Publication statusPublished - 1985

Fingerprint

Medroxyprogesterone
Aminoglutethimide
Clinical Trials
Breast Neoplasms
Hydrocortisone
Cortisone
Tamoxifen
Glucocorticoids

ASJC Scopus subject areas

  • Oncology

Cite this

A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma : Low response in patients previously treated with medroxyprogesterone. / Alberto, Pierre; Mermillod, Bernadette; Kaplan, Eli; Goldhirsch, Aron; Obrecht, Jean Pierre; Jungi, Felix; Martz, Georg; Barrelet, Laurent; Cavalli, Franco.

In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 4, 1985, p. 423-428.

Research output: Contribution to journalArticle

Alberto, Pierre ; Mermillod, Bernadette ; Kaplan, Eli ; Goldhirsch, Aron ; Obrecht, Jean Pierre ; Jungi, Felix ; Martz, Georg ; Barrelet, Laurent ; Cavalli, Franco. / A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma : Low response in patients previously treated with medroxyprogesterone. In: European Journal of Cancer and Clinical Oncology. 1985 ; Vol. 21, No. 4. pp. 423-428.
@article{0347b48e71a747e8a2e4610fb256979a,
title = "A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone",
abstract = "In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32{\%}, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36{\%}. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.",
author = "Pierre Alberto and Bernadette Mermillod and Eli Kaplan and Aron Goldhirsch and Obrecht, {Jean Pierre} and Felix Jungi and Georg Martz and Laurent Barrelet and Franco Cavalli",
year = "1985",
doi = "10.1016/0277-5379(85)90031-8",
language = "English",
volume = "21",
pages = "423--428",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma

T2 - Low response in patients previously treated with medroxyprogesterone

AU - Alberto, Pierre

AU - Mermillod, Bernadette

AU - Kaplan, Eli

AU - Goldhirsch, Aron

AU - Obrecht, Jean Pierre

AU - Jungi, Felix

AU - Martz, Georg

AU - Barrelet, Laurent

AU - Cavalli, Franco

PY - 1985

Y1 - 1985

N2 - In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.

AB - In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.

UR - http://www.scopus.com/inward/record.url?scp=0021813945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021813945&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(85)90031-8

DO - 10.1016/0277-5379(85)90031-8

M3 - Article

C2 - 3891359

AN - SCOPUS:0021813945

VL - 21

SP - 423

EP - 428

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -